MET and neoplasm: The novelty of MYTX‐011, stems from the incorporation of pH‐dependent binding into an anti‐c‐MET antibody, which allows for selective release of its cytotoxic payload, valine citrulline monomethyl auristatin E (vcMMAE), within the acidic microenvironment of tumour cells [112].